technetium-tc-99m-exametazime and Thrombosis

technetium-tc-99m-exametazime has been researched along with Thrombosis* in 10 studies

Reviews

1 review(s) available for technetium-tc-99m-exametazime and Thrombosis

ArticleYear
    Hand therapy, 2016, Volume: 21, Issue:1

    Trapeziometacarpal osteoarthritis is associated with more pain and restrictions than other hand osteoarthritis due to the functional importance of the thumb. While the effectiveness of surgical and pharmacological interventions has been widely examined, there is a lack of specific evidence about conservative non-pharmacological trapeziometacarpal osteoarthritis therapies. The objective of this systematic review was to provide evidence-based knowledge on the effectiveness of physiotherapy and occupational therapy on pain, function and quality of life.. A literature search of Medline, CINAHL, PEDro, OTseeker, EMB Dare Cochrane Database of Systematic Reviews and Cochrane CENTRAL was performed. Randomized and quasi-randomized controlled trials and corresponding systematic reviews, observational studies, pragmatic studies and case-control studies were included. The risk of bias was assessed.. Physical and occupational therapy-related interventions, especially multimodal interventions, seem to be effective to treat pain in patients with trapeziometacarpal osteoarthritis. Pre-fabricated neoprene splints and custom-made thermoplastic splints may reduce pain equally. Single interventions seem not to be effective. Significant evidence for effectiveness on function and quality of life could not be found.. The sole Na. The SUV. Genetic variants of

    Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; Animals; Animals, Zoo; Anti-Bacterial Agents; Anticoagulants; Antifungal Agents; Antimanic Agents; Antioxidants; Aortic Valve; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Bacillus; Bacterial Toxins; Bacterial Typing Techniques; Base Composition; Beauveria; Binge Drinking; Biomarkers; Bipolar Disorder; Blood Coagulation; Blotting, Western; Brachytherapy; Calcium Channels, L-Type; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Wall; Cells, Cultured; Ceramics; Chi-Square Distribution; China; Chlorophyll; Chlorophyta; Chloroplasts; Cholesterol, HDL; Chromatography, High Pressure Liquid; Chromobacterium; Clostridium perfringens; Clozapine; Constriction, Pathologic; Coronary Artery Bypass; Corticotropin-Releasing Hormone; Cross-Sectional Studies; Cytochrome P-450 CYP2C9; Dental Porcelain; Dental Restoration Failure; Dental Stress Analysis; Designer Drugs; Diaminopimelic Acid; DNA Fingerprinting; DNA, Bacterial; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Dosage Calculations; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Elasticity Imaging Techniques; Epsilonproteobacteria; Equipment Design; Ericaceae; Excitatory Amino Acid Antagonists; False Negative Reactions; Fatty Acids; Female; Food Analysis; Fresh Water; Gene Expression Regulation, Neoplastic; Glutathione; Graft Occlusion, Vascular; Heart Valve Prosthesis Implantation; Heart Ventricles; HEK293 Cells; Hemolymph; Humans; Hyaluronan Receptors; Hydrogen Peroxide; Hydrothermal Vents; Indoles; Inflammation Mediators; Inhibitory Concentration 50; Insecta; International Normalized Ratio; Isotope Labeling; Itraconazole; Kidney; Kinetics; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lamotrigine; Lanthanoid Series Elements; Limit of Detection; Linear Models; Lipid Peroxidation; Liver; Liver Cirrhosis; Logistic Models; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Malondialdehyde; Mediastinum; Metronidazole; Mice; Mice, Nude; Mice, Transgenic; Microbial Sensitivity Tests; Microscopy, Fluorescence; Middle Aged; Monocytes; Monomeric GTP-Binding Proteins; Multivariate Analysis; Myocytes, Cardiac; Neoplasm Staging; Neoplastic Stem Cells; Neural Pathways; Nitrates; Nucleic Acid Hybridization; Octamer Transcription Factor-3; Odds Ratio; Oxidation-Reduction; Oxidative Stress; Peptidoglycan; Phantoms, Imaging; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Phospholipids; Photolysis; Photosynthesis; Phylogeny; Plant Extracts; Polychaeta; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Preoperative Care; Prostatic Neoplasms; Pseudomonas aeruginosa; Pyrimidines; Pyrroles; Quorum Sensing; Radiology, Interventional; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Reference Values; Regression Analysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Rhizosphere; Risk Factors; RNA, Ribosomal, 16S; ROC Curve; Rutin; Saphenous Vein; Seawater; Selenium; Semen Preservation; Sensitivity and Specificity; Septal Nuclei; Sequence Analysis, DNA; Serum Albumin; Serum Albumin, Human; Shear Strength; Sodium Pertechnetate Tc 99m; Sodium-Hydrogen Exchangers; Soil Microbiology; SOXB1 Transcription Factors; Spain; Species Specificity; Sperm Motility; Spermatozoa; Spheroids, Cellular; Spores, Fungal; Stroke; Superoxide Dismutase; Swine; Tandem Mass Spectrometry; Technetium Compounds; Technetium Tc 99m Exametazime; Technetium Tc 99m Sestamibi; Temperature; Thiosulfates; Thrombosis; Thyroid Neoplasms; Transducers; Transfection; Transplantation, Heterologous; Treatment Outcome; Triazines; Tumor Burden; Urocortins; Uterine Cervical Neoplasms; Vacuoles; Valproic Acid; Ventral Tegmental Area; Vitamin K 2; Vitamin K Epoxide Reductases; Warfarin; Water Microbiology; Young Adult

2016

Trials

1 trial(s) available for technetium-tc-99m-exametazime and Thrombosis

ArticleYear
Transjugular intrahepatic portosystemic shunt (TIPS). Thrombogenicity in stents and its effect on shunt patency.
    Acta radiologica (Stockholm, Sweden : 1987), 1997, Volume: 38, Issue:4 Pt 1

    To compare the thrombogenicity and patency of the Palmaz stent and the Wallstent, and to evaluate the effect of periprocedural heparin therapy in cirrhotic patients with maintained coagulation capacity who receive a transjugular intrahepatic portosystemic shunt (TIPS).. Twenty-four patients were randomized into 4 groups of 6 patients. Each received a Palmaz-stent or Wallstent TIPS with or without periprocedural heparin therapy. The groups receiving periprocedural heparin were given 24 U/kg b.w. just before stent placement, followed by 24 h therapeutic i.v. heparin. After 24 hours, all patients received i.v. heparin for 1 week followed by subcutaneous treatment with low-molecular-weight heparin (0.3 ml/day) for another 4 weeks. Stent thrombogenicity was determined scintigraphically after i.v. injection of 120-290 mBq of 99mTc-labeled platelets at the time of stent placement and expressed as the stent/heart ratio. Shunt patency was assessed by duplex sonography and confirmed radiologically.. The aggregation ratio was highest 90 min after stent implantation. Wallstents showed a significantly higher ratio than Palmaz stents. Heparin reduced the ratio in patients with a Wallstent (-41%) but had no effect on Palmaz stents. Patients with a Wallstent without heparin had a higher rate of early shunt insufficiency (66.6%) than the other patients (0-16.6%). Primary assisted long-term patency was similar in the 4 groups.. Wallstents were more thrombogenic than Palmaz stents and gave a significantly higher risk of early shunt insufficiency in cirrhotic patients with maintained coagulation capacity. Periprocedural heparin was effective in the prevention of shunt insufficiency and is therefore indicated in such patients.

    Topics: Anticoagulants; Blood Platelets; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Intraoperative Care; Liver Cirrhosis; Male; Middle Aged; Organotechnetium Compounds; Oximes; Platelet Aggregation; Portal System; Portasystemic Shunt, Transjugular Intrahepatic; Postoperative Care; Radionuclide Imaging; Stents; Technetium Tc 99m Exametazime; Thrombosis; Ultrasonography

1997

Other Studies

8 other study(ies) available for technetium-tc-99m-exametazime and Thrombosis

ArticleYear
Evaluation of brain perfusion using Tc-99m HMPAO in a patient with a persistent vegetative neurologic state and a left ventricular thrombus.
    Clinical nuclear medicine, 2002, Volume: 27, Issue:12

    Topics: Brain; Cerebral Infarction; Chronic Disease; Heart Ventricles; Humans; Incidental Findings; Magnetic Resonance Imaging; Male; Middle Aged; Persistent Vegetative State; Radiography; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Exametazime; Thrombosis; Ventricular Dysfunction, Left

2002
Tc-99m HMPAO labeled platelets in the detection of left ventricular thrombosis post acute myocardial infarction.
    Clinical nuclear medicine, 1996, Volume: 21, Issue:11

    A left ventricular thrombosis post acute myocardial infarction was detected with Tc-99m HMPAO labeled platelet imaging. The left ventricular thrombosis was already detected on early scans, which allowed for a precise diagnosis during the first 6 hours of the study.

    Topics: Aged; Blood Platelets; Heart Diseases; Heart Ventricles; Humans; Male; Myocardial Infarction; Organotechnetium Compounds; Oximes; Radionuclide Imaging; Technetium Tc 99m Exametazime; Thrombosis

1996
Case report: chronic mesenteric ischaemia as a cause of abnormal bowel uptake of labelled leucocytes.
    The British journal of radiology, 1995, Volume: 68, Issue:814

    Chronic mesenteric ischaemia is often difficult to diagnose. A high level of clinical suspicion is needed and further investigation requires invasive procedures. We present a case where weight loss and abdominal pain were dominant features and initial interpretation of a labelled leucocyte scan suggested inflammatory bowel disease. Subsequent investigations excluded this possibility and chronic ischaemia was confirmed at autopsy. Positive small bowel images using 99Tcm-HMPAO labelled leucocytes may indicate chronic ischaemia.

    Topics: Aged; Chronic Disease; Fatal Outcome; Female; Humans; Intestine, Small; Leukocytes; Mesenteric Vascular Occlusion; Organotechnetium Compounds; Oximes; Radionuclide Imaging; Technetium Tc 99m Exametazime; Thrombosis

1995
Quantitation of thrombogenicity of hemodialyzer with technetium-99m and indium-111 labeled platelets.
    Nuclear medicine and biology, 1993, Volume: 20, Issue:5

    The platelet thrombogenicity of a hemodialyzer was quantified with 99mTc- and 111In-labeled platelets. The platelets collected from blood of Beagle dogs, Yorkshire pigs and human volunteers were labeled with 111In-tropolone (detergent-free) and 99mTc-HMPAO. Hemodialysis was performed with a hollow-fiber dialyzer (HFD) in a flow-loop, the temperature of which was maintained at 37 degrees C, with flow-rates of 7, 150 and 270 mL/min; after dialysis, the HFD radioactivity was measured with an ionization chamber and imaged with a gamma-camera. The radioactivity of samples of hollow-fibers taken from the top, middle and bottom of the dialyzer was determined with a gamma-counter. The mean values of hemodialyzer-adherent platelet radioactivity were calculated for both radionuclides. The canine platelets were found to be more thrombogenic than porcine and human platelets. The adhesivity of porcine platelets to the biomaterial (cellulose-acetate) of the dialyzer approximated that of human platelets. The 99mTc label underestimated the thrombus formation (P < 0.01). The dynamic processes of thrombosis and embolization from the hemodialyzer resulted in the large standard deviations around the mean values of the adherent thrombus. In spite of this limitation of the dynamic pathology, the quantitation of comparative thrombogenicity with 111In- and 99mTc-labeled platelets suggests that both radionuclides could be used for measurement of device-induced thrombogenicity and may provide an estimation of prosthesis-induced thrombogenicity of human platelets from animal studies.

    Topics: Animals; Blood Platelets; Dogs; Humans; Indium Radioisotopes; Organotechnetium Compounds; Oximes; Renal Dialysis; Species Specificity; Swine; Technetium Tc 99m Exametazime; Thrombosis; Tropolone

1993
Tc-99m-HMPAO labelled human platelets: in vitro and in vivo results.
    European journal of nuclear medicine, 1989, Volume: 15, Issue:6

    The lipophilic 99mTc-HMPAO complex can be used for labelling platelets as well as granulocytes. Platelets were isolated according to standard isolation procedures for the evaluation of the optimal labelling parameters. The labelling efficiency (%) depends on incubation temperature (22 degrees C: 40%: 37 degrees C: 50%), incubation time (3 min: 20%, 25 min: 55%) and the incubation medium (plasma: 40%; saline 50%). The 60 min 99mTc elution out of the platelets ranged around 8%. The platelet recovery used as a quality control parameter is around 25% +/- 4% and is stable for at least 240 min. The high elution rate out of the platelets leads to renal excretion of the label and hence to significant kidney and bladder activity. Intestinal excretion of the label can also be frequently demonstrated. Fresh thrombotic lesions can normally be detected 4 h after reinjection of the labelled platelets, and in some patients as early as 1 h after reinjection. In conclusion, 99mTc-HMPAO seems to be a promising platelet label for imaging thrombotic lesions but not for platelet survival studies, because of the short physical half life of 99mTc.

    Topics: Blood Platelets; Cell Survival; Female; Half-Life; Humans; In Vitro Techniques; Isotope Labeling; Male; Organometallic Compounds; Oximes; Radionuclide Imaging; Technetium; Technetium Tc 99m Exametazime; Thrombosis

1989
99Tcm hexamethylpropyleneamineoxime (HMPAO) as a platelet label: evaluation of labelling parameters and first in vivo results.
    Nuclear medicine communications, 1988, Volume: 9, Issue:10

    The lipophilic 99Tcm hexamethylpropyleneamineoxime (HMPAO) complex can be used for labelling platelets as well as granulocytes. For the evaluation of optimal labelling parameters, platelets were isolated according to standard isolation procedures. The labelling efficiency (%) depends on incubation temperature (22 degrees C: 40%; 37 degrees C: 50%), incubation time (3 min: 20%; 25 min: 55%) and the incubation medium (plasma: 40%; saline: 50%). The 60 min 99Tcm elution from the platelets is around 8%. The platelet recovery, used as a quality parameter, is around 25 +/- 4% and is stable for at least 240 min. The high elution rate from the platelets leads to renal excretion of the label and so to significant kidney and bladder activity. Intestinal excretion of the label can also be frequently demonstrated. Fresh thrombotic lesions can usually be detected 4 h after reinjection of the labelled platelets, and in some patients as early as 1 h after reinjection of the platelets. In conclusion, 99Tcm HMPAO seems to be a promising platelet label for imaging thrombotic lesions but not for platelet-survival studies because of the short physical half-life of 99Tcm.

    Topics: Blood Platelets; Humans; Isotope Labeling; Organometallic Compounds; Oximes; Radionuclide Imaging; Technetium; Technetium Tc 99m Exametazime; Thrombosis

1988
Investigations to determine the optimum conditions for radiolabelling human platelets with 99Tcm-hexamethyl propylene amine oxime (99Tcm-HM-PAO)
    Nuclear medicine communications, 1988, Volume: 9, Issue:4

    99Tcm-hexamethyl propylene amine oxime (99Tcm-HM-PAO) has been evaluated as an agent to radiolabel human platelets in vitro. The rate of uptake of this lipophilic complex, the effect of HM-PAO, plasma and platelet concentration were measured to determine the optimum conditions for radiolabelling platelets for short-term clinical investigations of thromboses. The complex was made according to the manufacturer's instructions and immediately added to isolated platelets in vitro. The rate of labelling was slower than for leucocytes, reaching a plateau after approximately 40 min at room temperature (RT). Increasing the temperature to 37 degrees C did not increase the labelling efficiency (LE). Addition of plasma to platelets at a cell concentration of 1 x 10(9) [corrected] ml-1 reduced the LE from 66% in saline to 52% in 20% ACD-plasma. However, increasing the platelet concentration from 5 x 10(8) to 2 x 10(9) ml-1, increased the LE from 9 to 76% for platelets labelled in 20% plasma for 30 min at RT. The in vitro stability of the 99Tcm in the labelled cells showed that 7% of the radioactivity were immediately released from the platelets and a further 13% were eluted during a 60 min incubation in plasma at 37 degrees C. It has been concluded that incubation of platelets at RT with 99Tcm-HM-PAO containing 80 micrograms ml-1 HM-PAO at a cell concentration of 1 x 10(9) ml-1 or greater, results in a high LE, with more than 85% of the 99Tcm being retained by the platelets during a 60 min incubation in plasma.

    Topics: Blood Platelets; Drug Evaluation; Humans; Organometallic Compounds; Oximes; Radionuclide Imaging; Technetium; Technetium Tc 99m Exametazime; Temperature; Thrombosis; Time Factors

1988
Tc-99m-HMPAO: a new platelet labelling compound?
    European journal of nuclear medicine, 1987, Volume: 13, Issue:5

    Topics: Aged; Blood Platelets; Heart Ventricles; Humans; Male; Organometallic Compounds; Oximes; Radionuclide Imaging; Technetium Tc 99m Exametazime; Thrombosis

1987